mCRPC

Sequencing in metastatic prostate cancer: Choose The Right Card (accreditation requested)

15 years of progress in mCRPC; Optimal use of the currently available agents

Speaker
Prof. Dr. Ronald De Wit, Erasmus MC Cancer Institutem, Rotterdam, The Netherlands

Presentator
Jan Van Parijs

Hoe CP's behalen? Comment obtenir des CP?

Management of advanced prostate cancer: from clinical experience to personalized medicine (accreditation valid from 07/11/2018 up to 06/11/2019 - 1 CP)

Speaker
Dr. De Maeseneer, AZ St.-Lucas Brugge, UZ Gent

Speaker
Prof. Tombal, UCL Woluwe

Presentator
Jan Van Parijs

Hoe CP's behalen? Comment obtenir des CP?

Therapeutic sequencing – no guidelines, so how to proceed in real life practice (Accreditation valid from 24/10/2017 up to 23/10/2018 - 1 CP)

Speaker
Prof. Dr. S Rottey

Speaker
Dr. A. Bahl

Presentator
Jan van Parijs

Hoe CP's behalen? Comment obtenir des CP?

Are we targeting prostate cancer heterogeneity in the right way? (accreditation valid from 14/06/2017 up to 13/06/2018 - 1 CP)

Speaker
Prof. Bertrand Tombal
UCL Woluwe

Moderator
Dr Piet Dirix
GZA Antwerp

Presentator
Jan van Parijs

Cross-resistances between PCa drugs and therapeutic implications (accreditation valid from 16/11/2016 up to 15/11/2017 - 1 CP)

Spreker 1: Dr. Peter Schatteman, urologist, OLV Ziekenhuis Aalst, Belgium

Spreker 2: Dr. Robert van Soest, Dept. of Urology, Erasmus University Medical Center, Rotterdam, the Netherlands

Presentator: Jan van Parijs

Assessment and treatment of geriatric patients with metastatic prostate cancer? (accreditation valid from 03/10/2016 up to 02/10/2017 - 1 CP)

Epidemiology & risks of PCa in the elderly population

Need of accurate assessment of senior adults with PCA ?

Treatment decision in older patients with cancer

Geriatric assessment & tools

Practical application of geriatric assessment

2 clinical cases + therapeutic approaches

Conclusion: Call to action & SIOG guidelines

Speakers:
Pr. Steven Joniau, KU Leuven
Mrs. Cindy Kenis, KU Leuven

Monitoring of PCa treatments (accreditation valid from 17/05/2016 up to 16/05/2017 - 1 CP)

Introduction : Dr Seront ( Jolimont-La Louviere)

“Role of an accurate imaging tool”

Optimal staging

Response evaluation

Core presentation: Pr Lecouvet ( UCL Woluwé)

“Bone metastasis –Modern imaging –detection & response”

Bone metastasis - Detection

Different techniques

Standard algoritm

MRI

Axial skeleton MRI

WB-MRI

Bone metastasis – Impact of new techniques on patient management

Bone metastasis – response

Flare phenomenon

New algoritm for metastatic work-up

Questions & Answers

12.05.16 at 8.00 PM

Accreditation requested in collaboration with Vesaliana vzw

(accreditation valid from 17/05/2016 up to 16/05/2017 - 1 CP)

Speakers: Pr. Lecouvet ( UCL Woluwe)
Moderator: Dr. Seront (Jolimont)

Current principles for mCRPC: therapy & personalized medicine (accreditation valid from 01/04/2016 up to 31/03/2017)

Introduction : Pr Joniau ( UZ Leuven)

“Clonal heterogeneity of prostate cancer – one drug doesn’t fit all patients”

Core presentation: Pr Tombal ( UCL Woluwé)

“Current principles for mCRPC : therapy & personalized medicine ”

Prostate cancer is an androgen dependant disease

Prostate cancer is also an androgen-independent disease

Because of sustained pressure

Cross-resistance between drugs

Limited sensitivity to docetaxel

Because of co-existence of AR independent pathways

Primary resistance to AR targeted-agents

How to recognize & How to treat ?

Prostate is a heterogeneous patchwork of AR-dependant & independent clones

Monitoring by imaging

Questions & Answers

“Advanced prostate cancer is a heterogeneous disease and must consequently be treated based on the biology of the disease. This statement will be raised by Prof Tombal (UCL) and discussions moderated by Prof Joniau ( KUL).”

Speaker: Prof. Tombal, UCL Woluwé

Moderator: Prof. Joniau, KUL Leuven